Teva Pharmaceuticals Industries Ltd., commonly known as Teva, is a global leader in the pharmaceutical industry, headquartered in Israel (IL). Founded in 1901, Teva has established a strong presence in over 60 countries, focusing on the development, production, and marketing of generic and specialty medicines. With a diverse portfolio that includes a wide range of therapeutic areas such as central nervous system disorders, oncology, and respiratory conditions, Teva is renowned for its commitment to accessibility and innovation. The company’s core products, including the widely used Copaxone and a robust selection of generic medications, set it apart in a competitive market. Teva's notable achievements include being one of the largest generic drug manufacturers globally, reflecting its significant market position and dedication to improving patient outcomes through affordable healthcare solutions.
How does Teva Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Teva Pharmaceuticals's score of 85 is higher than 92% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Teva Pharmaceuticals reported total greenhouse gas (GHG) emissions of approximately 4,066,116,000 kg CO2e across all scopes. This includes about 243,603,000 kg CO2e from Scope 1 emissions and approximately 218,504,000 kg CO2e from Scope 2 emissions (market-based). The company also disclosed significant Scope 3 emissions, amounting to about 4,066,116,000 kg CO2e, which encompasses various categories such as purchased goods and services, use of sold products, and end-of-life treatment of sold products. Teva has set ambitious reduction targets, aiming to reduce absolute Scope 1 and 2 GHG emissions by 25% by 2025 and by 46% by 2030, using 2019 as the baseline year. Additionally, the company has committed to reducing absolute Scope 3 emissions by 25% by 2030, with a 2020 baseline. These targets are aligned with the Science Based Targets initiative (SBTi) and are designed to support the global effort to limit warming to 1.5°C. Furthermore, Teva has announced its intention to achieve net zero emissions across its operations and value chain by 2045. This long-term commitment reflects the company's dedication to sustainability and climate action. Overall, Teva Pharmaceuticals is actively working towards significant emissions reductions while maintaining transparency in its reporting and commitments.
Access structured emissions data, company-specific emission factors, and source documents
2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 438,420,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | 613,541,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 3 | - | - | - | - | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Teva Pharmaceuticals is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.